Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 29 entities : Pfizer, inc. save search
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results topline license phase 3 ulcerative colitis
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 1.83%
H: 3.58%
C: 1.77%
covid-19 authorization vaccine order emergency use authorization
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -1.87%
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
fda approval hiv order
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results phase 3 topline ulcerative colitis
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.